NCT05318326 is a Phase 3 clinical trial of Yogliptin 400mg group in Type 2 Diabetes, sponsored by Chengdu Easton Biopharmaceuticals Co,Ltd.

Who is sponsoring NCT05318326?

NCT05318326 is sponsored by Chengdu Easton Biopharmaceuticals Co,Ltd.

What drugs are being tested in NCT05318326?

Interventions in NCT05318326: placebo group, Yogliptin 400mg group, Yogliptin 200mg group.

What condition does NCT05318326 study?

NCT05318326 studies Type 2 Diabetes.

Is NCT05318326 still recruiting?

NCT05318326 is currently status unknown. Last updated 20 April 2022.

Last reviewed 2022-04-20 · How we verify

NCT05318326

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Evaluate the Clinical Efficacy and Safety of Yogliptin Tablets

Status unknown Phase 3 Last updated 20 April 2022

What this trial tests

Phase 3 trial testing placebo group in Type 2 Diabetes in 450 participants. Status unknown.

Timeline

1 January 2022

Primary endpoint
31 December 2024

31 December 2024

Quick facts

Lead sponsor	Chengdu Easton Biopharmaceuticals Co,Ltd
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	450
Start date	1 January 2022
Primary completion	31 December 2024
Estimated completion	31 December 2024
Sites	1 location across China

Drugs / interventions tested

placebo group
Yogliptin 400mg group — full drug profile →
Yogliptin 200mg group — full drug profile →

Conditions studied

Type 2 Diabetes — all drugs for Type 2 Diabetes →

Sponsor

Chengdu Easton Biopharmaceuticals Co,Ltd — full company profile →

Who can join

Adults 18 to 75, any sex, with Type 2 Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to assess the efficacy of Yogliptin (as monotherapy) compared with placebo after 24 weeks, and the safety (up to 52 weeks) of Yogliptin in Chinese patients with Type 2 diabetes who are insufficient glycaemic control with diet and exercise.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Signaling pathways in obesity: mechanisms and therapeutic interventions.
Wen X, Zhang B, Wu B, Xiao H, et al · · 2022 · cited 245× · PMID 36031641 · DOI 10.1038/s41392-022-01149-x

Verify or expand the search:

Other recruiting trials for Type 2 Diabetes

Currently open trials in the same condition.

NCT07053319 — SGLT2i, Pioglitazone, and Ketone Production in T2D · Phase 1 · recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07463859 — Effects of Periodontal Treatment Associated With Antimicrobial Photodynamic Therapy on Halitosis in Patients With Diabet · NA · recruiting
NCT07254689 — The Food for Health Study · NA · recruiting
NCT07558863 — Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05318326 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chengdu Easton Biopharmaceuticals Co,Ltd
Last refreshed: 20 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05318326.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing